Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 3/2007

Open Access 01-06-2007 | Research

Hemodynamic goals in randomized clinical trials in patients with sepsis: a systematic review of the literature

Authors: Jonathan E Sevransky, Seema Nour, Gregory M Susla, Dale M Needham, Steven Hollenberg, Peter Pronovost

Published in: Critical Care | Issue 3/2007

Login to get access

Abstract

Introduction

Patients with sepsis suffer high morbidity and mortality. We sought to conduct a systematic review of the literature to evaluate the association between hemodynamic goals of therapy and patient outcomes.

Methods

We conducted a comprehensive search of the literature to systematically review hemodynamic goals used in clinical trials in patients with sepsis. We searched the literature using the Pubmed (1965–June 2006), Embase (1974–June 2006), CINAHL (1982–June 2006), pre-CINAHL, and Cochrane Library (2006, issue 3) electronic databases on 1 August 2006 for the following terms: sepsis, septic shock, severe sepsis, human clinical trials. We also hand-searched references and our personal files. Studies were selected if they met all of the following criteria: randomized, controlled trial study design; enrollment of adult patients with sepsis; presence of a hemodynamic goal for patient management; > 24-hour follow-up; and survival included as an outcome. Studies were independently selected and reviewed by two investigators.

Results

A total of 6,006 citations were retrieved, and 13 eligible articles were reviewed. Mean arterial pressure was a treatment goal in nine studies, and systolic blood pressure was a treatment goal in three studies. A goal for pulmonary artery occlusion pressure, central venous pressure, and cardiac index was given in four, three, and five studies, respectively. The range of hemodynamic goals used in the trials were: mean arterial pressure 60–100 mmHg, central venous pressure 6–13 mmHg, pulmonary artery occlusion pressure 13–17 mmHg, and cardiac index 3–6 l/min/m2. All trials that used a systolic blood pressure goal used 90 mmHg as the aim.

Conclusion

For those trials that specify hemodynamic goals, the wide range of treatment targets suggest a lack of agreement on blood pressure and filling pressure goals for management of patients with sepsis. There was also inconsistency between trials in which measures were targeted. Further research is necessary to determine whether this lack of consistency in hemodynamic goals may contribute to heterogeneity in treatment effects for clinical trials of novel sepsis therapies.
Appendix
Available only for authorised users
Literature
1.
Laupland KB, Zygun DA, Doig CJ, Bagshaw SM, Svenson LW, Fick GH: One-year mortality of bloodstream infection-associated sepsis and septic shock among patients presenting to a regional critical care system. Intensive Care Med 2005,31(2):213-9. 10.1007/s00134-004-2544-6CrossRefPubMed
2.
Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the united states from 1979 through 2000. N Engl J Med 2003, 348: 1546-1554. 10.1056/NEJMoa022139CrossRefPubMed
3.
Annane D, Aegerter P, Jars-Guincestre MC, Guidet B, for the CUB-Rea Network: Current epidemiology of septic shock: the CUB-rea network. Am J Respir Crit Care Med 2003, 168: 165-172. 10.1164/rccm.2201087CrossRefPubMed
4.
Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, for the Surviving Sepsis Campaign Management Guidelines Committee, et al.: Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004, 32: 858-873. 10.1097/01.CCM.0000117317.18092.E4CrossRefPubMed
5.
Zeni F, Freeman B, Natanson C: Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997, 25: 1095-1100. 10.1097/00003246-199707000-00001CrossRefPubMed
6.
Hollenberg SM: For every complex problem, there is a solution that is simple ... and wrong. Crit Care Med 2000, 28: 3088-3089. 10.1097/00003246-200008000-00074CrossRefPubMed
7.
Wheeler AP, Bernard GR: Treating patients with severe sepsis. N Engl J Med 1999, 340: 207-214. 10.1056/NEJM199901213400307CrossRefPubMed
8.
Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101: 1644-1655.CrossRefPubMed
9.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996, 17: 1-12. 10.1016/0197-2456(95)00134-4CrossRefPubMed
10.
Peake SL, Moran JL, Leppard PI: N -acetyl-L-cysteine depresses cardiac performance in patients with septic shock. Crit Care Med 1996, 24: 1302-1310. 10.1097/00003246-199608000-00006CrossRefPubMed
11.
Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A: Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998, 26: 645-650. 10.1097/00003246-199804000-00010CrossRefPubMed
12.
Tuchschmidt J, Fried J, Astiz M, Rackow E: Elevation of cardiac output and oxygen delivery improves outcome in septic shock. Chest 1992, 102: 216-220.CrossRefPubMed
13.
Cole L, Bellomo R, Hart G, Journois D, Davenport P, Tipping P, Ronco C: A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 2002, 30: 100-106. 10.1097/00003246-200201000-00016CrossRefPubMed
14.
Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001, 345: 1368-1377. 10.1056/NEJMoa010307CrossRefPubMed
15.
Boldt J, Papsdorf M, Piper SN, Rothe A, Hempelmann G: Continuous heparinization and circulating adhesion molecules in the critically ill. Shock 1999, 11: 13-18.CrossRefPubMed
16.
Emet S, Memis D, Pamukcu Z: The influence of N -acetyl-L-cystein infusion on cytokine levels and gastric intramucosal pH during severe sepsis. Crit Care 2004, 8: R172-R179. 10.1186/cc2866PubMedCentralCrossRefPubMed
17.
Briegel J, Forst H, Hallar M, Schelling G, Kilger E, Kuprat G, Hemmer B, Hummel T, Lenhart A, Heyduck M, Stoll C, Peter K: Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single center study. Crit Care Med 1999, 27: 723-732. 10.1097/00003246-199904000-00025CrossRefPubMed
18.
Alia I, Esteban A, Gordo F, Lorente JA, Diaz C, Rodriguez JA, Frutos F: A randomized and controlled trial of the effect of treatment aimed at maximizing oxygen delivery in patients with severe sepsis or septic shock. Chest 1999, 115: 453-461. 10.1378/chest.115.2.453CrossRefPubMed
19.
Spapen H, Zhang H, Demanet C, Vleminckx W, Vincent JL, Huyghens L: Does N -acetyl-L-cysteine influence cytokine response during early human septic shock? Chest 1998, 113: 1616-1624.CrossRefPubMed
20.
Bakker J, Grover R, McLuckie A, Holzapfel L, Andersson J, Lodato R, Watson D, Grossman S, Donaldson J, Takala J: Administration of the nitric oxide synthase inhibitor N G -methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med 2004, 32: 1-12. 10.1097/01.CCM.0000105118.66983.19CrossRefPubMed
21.
Lopez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D: Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004, 32: 21-30. 10.1097/01.CCM.0000105581.01815.C6CrossRefPubMed
22.
Hollenberg SM, Ahrens TS, Annane D, Astiz ME, Chalfin DB, Dasta JF, Heard SO, Martin C, Napolitano LM, Susla GM, Totaro R, Vincent J-L, Zanotti-Cavazzoni S: Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med 2004, 32: 1928-1948. 10.1097/01.CCM.0000139761.05492.D6CrossRefPubMed
23.
Clark M, Plank L, Connolly A, Streat SJ, Hill AA, Gupta R, Monk DN, Shenkin A, Hill GL: Effect of a chimeric antibody to tumor necrosis factor alpha on cytokine and physiologic responses in patients with severe sepsis. A randomized clinical trial. Crit Care Med 1998, 26: 1650-1659. 10.1097/00003246-199810000-00016CrossRefPubMed
24.
Kumar A, Anel R, Bunnell E, Zanotti S, Habet K, Haery C, Marshall S, Cheang M, Neumann A, Ali A, Kavinsky C, Parrillo JE: Preload-independent mechanisms contribute to increased stroke volume following large volume saline infusion in normal volunteers: a prospective interventional study. Crit Care 2004, 8: R128-R136. 10.1186/cc2844PubMedCentralCrossRefPubMed
25.
Fowler RA, Cook DJ: The arc of the pulmonary artery catheter. JAMA 2003, 290: 2732-2734. 10.1001/jama.290.20.2732CrossRefPubMed
26.
Gattinoni L, Brazzi L, Pelosi P, Latini R, Tognoni G, Pesenti A, Fumagalli R: A trial of goal-oriented hemodynamic therapy in critically ill patients. N Engl J Med 1995, 333: 1025-1032. 10.1056/NEJM199510193331601CrossRefPubMed
27.
Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, et al.: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 2003, 290: 238-247. 10.1001/jama.290.2.238CrossRefPubMed
28.
Abraham E, Laterre P, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, et al.: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005, 353: 1332-1341. 10.1056/NEJMoa050935CrossRefPubMed
29.
Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, et al.: High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001, 1869-1878. 10.1001/jama.286.15.1869
30.
Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, Dal Nogare A, Nasraway S, Berman S, Cooney R, et al.: Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II study group. Lancet 1998, 351: 929-933.CrossRefPubMed
31.
Osman D, Ridel C, Ray P, Monnet X, Anguel N, Richard C, Teboul JL: Cardiac filling pressures are not appropriate to predict hemodynamic response to volume challenge. Crit Care Med 2007, 35: 64-68. 10.1097/01.CCM.0000249851.94101.4FCrossRefPubMed
32.
Ely EW, Baker AM, Dunagan DP, Burke HL, Smith AC, Kelly PT, Johnson MM, Browder RW, Bowton DL, Haponik EF: Effect on the duration of mechanical ventilation of identifying patients capable of breathing spontaneously. N Engl J Med 1996, 335: 1864-1869. 10.1056/NEJM199612193352502CrossRefPubMed
33.
Wheeler AP, Bernard GR, Thompson BT, Schoenfeld D, Wiedemann HP, deBoisblanc B, Connors AF Jr, Hite RD, Harabin AL, National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network: Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med 2006, 354: 2213-2224. 10.1056/NEJMoa061895CrossRefPubMed
34.
Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B, Connors AF Jr, Hite RD, Harabin AL, National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network: Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006, 354: 2564-2575. 10.1056/NEJMoa062200CrossRefPubMed
35.
Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, Van Wijngaerden E, Bobbaers H, Bouillon R: Intensive insulin therapy in the medical ICU. N Engl J Med 2006, 354: 449-461. 10.1056/NEJMoa052521CrossRefPubMed
36.
Taylor BE, Schallom ME, Sona CS, Buchman TG, Boyle WA, Mazuski JE, Schuerer DE, Thomas JM, Kaiser C, Huey WY, Ward MR, et al.: Efficacy and safety of an insulin infusion protocol in a surgical ICU. J Am Coll Surg 2006, 202: 1-9. 10.1016/j.jamcollsurg.2005.09.015CrossRefPubMed
Metadata
Title
Hemodynamic goals in randomized clinical trials in patients with sepsis: a systematic review of the literature
Authors
Jonathan E Sevransky
Seema Nour
Gregory M Susla
Dale M Needham
Steven Hollenberg
Peter Pronovost
Publication date
01-06-2007
Publisher
BioMed Central
Published in
Critical Care / Issue 3/2007
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc5948

Other articles of this Issue 3/2007

Critical Care 3/2007 Go to the issue

Commentary

Pulse pressure variation: beyond the fluid management of patients with shock

Journal club critique

Steroids in early ARDS?

Review

Clinical review: Agitation and delirium in the critically ill – significance and management

Review

Bench-to-bedside review: Pulmonary–renal syndromes – an update for the intensivist

Research

A German national prevalence study on the cost of intensive care: an evaluation from 51 intensive care units

Commentary

A targeted extracorporeal therapy for endotoxemia: the time has come